Skip to main content
SpringerLink
Log in

Neurohormonal control becomes a key therapeutic goal in heart failure

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

Two years on from the inaugural heart failure conference initiated by the Working Group on Heart Failure of the European Society of Cardiology, the focus of therapy for this condition has shifted. The influence of neurohormonal modulation on the outcome of heart failure came under the spotlight at Heart Failure ’97 [ Cologne, Germany; May 1997 ]. Since the concept of using polypharmacy to relieve symptoms was mooted at Heart Failure ’95*, the therapeutic aims have widened to include the prevention of heart failure and slowing disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Ruth Whittington
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whittington, R. Neurohormonal control becomes a key therapeutic goal in heart failure. Inpharma Wkly. 1091, 3–5 (1997). https://doi.org/10.2165/00128413-199710910-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199710910-00003

Keywords

Search

Navigation